<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bekhterev</journal-id><journal-title-group><journal-title xml:lang="ru">Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева</journal-title><trans-title-group xml:lang="en"><trans-title>V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7053</issn><issn pub-type="epub">2713-055X</issn><publisher><publisher-name>V. M. BEKHTEREV  NATIONAL  RESEARCH  MEDICAL  CENTER  FOR  PSYCHIATRY  AND  NEUROLOGY                           OF    THE  RUSSIAN  FEDERATION   MINISTRY  OF  HEALTH</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31363/2313-7053-2020-4-82-93</article-id><article-id custom-type="elpub" pub-id-type="custom">bekhterev-488</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Современные методы коррекции когнитивных расстройств при эндогенных депрессиях</article-title><trans-title-group xml:lang="en"><trans-title>Contemporary approaches to correction of cognitive impairment in endogenous depression</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8344-0620</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олейчик</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Oleichik</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">i.oleichik@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9154-4104</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шишковская</surname><given-names>Т. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Shishkovskaia</surname><given-names>T. I.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">tszyszkowska@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4423-4007</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Баранов</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Baranov</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"/><email xlink:type="simple">pab1960@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр психического здоровья»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Mental Health Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2020</year></pub-date><volume>0</volume><issue>4</issue><fpage>82</fpage><lpage>93</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Олейчик И.В., Шишковская Т.И., Баранов П.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Олейчик И.В., Шишковская Т.И., Баранов П.А.</copyright-holder><copyright-holder xml:lang="en">Oleichik I.V., Shishkovskaia T.I., Baranov P.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bekhterevreview.com/jour/article/view/488">https://www.bekhterevreview.com/jour/article/view/488</self-uri><abstract><p>Одним из базовых симптомов эндогенной депрессии, к которому последние годы привлечено особое внимание исследователей, является когнитивная дисфункция. Ее наличие отмечается на инициальном этапе болезни, на высоте депрессии, а также после редукции ее основных проявлений, что, в значительной степени обуславливает ретенцию так называемых резидуальных депрессивных симптомов. Когнитивные нарушения во время депрессивного эпизода регистрируются как объективными методами (нейропсихологическим и психопатологическим), так и субъективно, по результатам стандартизированных опросов пациентов. По данным нейропсихологических методик, у больных депрессией отмечаются значимые отличия от здоровых лиц в сфере когнитивного функционирования по показателям исполнительских функций, рабочей памяти, пространственного мышления, скорости реагирования, вербального научения, непосредственного и отсроченного свободного воспроизведения. Существует ряд психофармакологических средств (преимущественно антидепрессантов), которые обладают доказанной прокогнитивной активностью при депрессиях. Кроме того, в литературе описаны ряд иных лекарственных и нелекарственных подходов к терапии когнитивной дисфункции при эндогенных депрессиях, которые представляются перспективными и многообещающими.</p></abstract><trans-abstract xml:lang="en"><p>Cognitive dysfunction is one of the basic symptoms of endogenous depression, gaining much of the researchers’ interest lately. It is observed at the initial stage, at the peak intensity of depressive symptoms and even after their reduction, which leads to the persistence of residual depressive state. Cognitive impairment during the depressive episode can be detected by objective methods (clinical and neuropsychological), and their subjective importance is being revealed by standardized questionnaires. Depressed patients show lower results in executive functions, working memory, reaction speed, verbal learning, immediate and delayed recall subtests of neuropsychological batteries. There are few pharmacological agents (mostly antidepressants) with well-proven procognitive activity in depression. Besides, some new pharmacological and non-pharmacological approaches for treatment of cognitive impairment in depression have appeared lately and are described in literature as promising.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>депрессия</kwd><kwd>когнитивные нарушения</kwd><kwd>прокогнитивный эффект</kwd><kwd>антидепрессанты</kwd><kwd>нелекарственные методы коррекции когнитивной дисфункции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>depression</kwd><kwd>cognitive impairment</kwd><kwd>procognitive effect</kwd><kwd>antidepressants</kwd><kwd>non-pharmacological methods for correction of cognitive impairment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Беккер Р.А., Быков Ю.В. Когнитивные нарушения при депрессиях: клиническое значение и современные возможности терапии. Психиатрия и психофармакотерапия. 2015;17(4):40-45.</mixed-citation><mixed-citation xml:lang="en">Беккер Р.А., Быков Ю.В.Bekker R.A., Bykov YuV. Kognitivnye narusheniya pri depressiyakh: klinicheskoe znachenie i sovremennye vozmozhnosti terapii. Psikhiatriya i psikhofarmakoterapiya. 2015;17(4):40-45.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Конорева А.Е., Мосолов С.Н. Когнитивные нарушения при биполярном аффективном расстройстве. Современная терапия психических расстройств. 2017;4:11-18.</mixed-citation><mixed-citation xml:lang="en">Konoreva A.E., Mosolov S.N. Kognitivnye narusheniya pri bipolyarnom affektivnom rasstroistve. Sovremennaya terapiya psikhicheskikh rasstroistv. 2017;4:11-18.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Медведев В.Э. Сигма-рецепторы: роль в лечении аффективных расстройств. Неврология, нейропсихиатрия, психосоматика. 2012:2.</mixed-citation><mixed-citation xml:lang="en">Medvedev V.Eh. Sigma-retseptory: rol’ v lechenii affektivnykh rasstroistv. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2012:2.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мирошниченко И.И. Способы повышения и восстановления когнитивных функций. Психиатрия. 2020;18:71-78.</mixed-citation><mixed-citation xml:lang="en">Miroshnichenko I.I. Sposoby povysheniya i vosstanovleniya kognitivnykh funktsii. Psikhiatriya. 2020;18(1):71-78.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Незнанов Н.Г., Мазо Г.Э., Рукавишников Г.В. Влияние антидепрессантов на когнитивные функции пациентов с депрессивным расстройством. Обозрение психиатрии и медицинской психологии имени ВМ Бехтерева. 2015;3:75-82.</mixed-citation><mixed-citation xml:lang="en">Neznanov N.G., Mazo G.Eh., Rukavishnikov G.V. Vliyanie antidepressantov na kognitivnye funktsii patsientov s depressivnym rasstroistvom. Obozrenie psikhiatrii i meditsinskoi psikhologii imeni VM Bekhtereva. 2015;3:75-82.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Петрова Н.Н., Янченко М.А. Депрессия и когнитивные нарушения. Неврологический вестник (журнал им. В.М. Бехтерева). 2017;49(4):21-29.</mixed-citation><mixed-citation xml:lang="en">Petrova, N.N., Yanchenko, M.A. Depressiya i kognitivnye narusheniya. Nevrёдорова А.И., Ахапкин Р.В., Файзуллоев А.З. Предикторы терапевтической динамики когнитивных нарушений при депрессивных расстройствах непсихотического уровня. Российский психиатрический журнал. 2019;1. Fedorova A.I., Akhapkin R.V., Faizulloev A.Z. Prediktory terapevticheskoi dinamiki kognitivnykh narushenii pri depressivnykh rasstroistvakh nepsik-hoticheskogo urovnya. Rossiiskii psikhiatricheskii zhurnal. 2019:1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Фёдорова А.И., Ахапкин Р.В., Файзуллоев А.З. Предикторы терапевтической динамики когнитивных нарушений при депрессивных расстройствах непсихотического уровня. Российский психиатрический журнал. 2019;1.</mixed-citation><mixed-citation xml:lang="en">Shagiakhmetov F.Sh., Anokhin P.K., Shamakina I.Yu. Vortioksetin: mekhanizmy mul’timodal’nosti i klinicheskaya ehffektivnost’. Sotsial’naya i klinicheskaya psikhiatriya. 2016:26(4).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Шагиахметов Ф.Ш., Анохин П.К., Шамакина И.Ю. Вортиоксетин: механизмы мультимодальности и клиническая эффективность. Социальная и клиническая психиатрия. 2016;26(4).</mixed-citation><mixed-citation xml:lang="en">Shmukler A.B. Znachenie kognitivnykh narushenii dlya otsenki patogeneza, klinicheskoi kartiny i lecheniya depressii. Sotsial’naya i klinicheskaya psikhiatriya. 2016:26(4).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шмуклер А.Б. Значение когнитивных нарушений для оценки патогенеза, клинической картины и лечения депрессии. Социальная и клиническая психиатрия. 2016:26(4).</mixed-citation><mixed-citation xml:lang="en">Yanushko M.G., Shamanina M.V., Aristova T.A., Richard K., Ivanov, M.V., &amp;amp; Tolmacheva, M. Standartizatsiya shkaly «Kratkaya otsenka kognitivnykh funktsii u patsientov s affektivnymi rasstroistvam»(BAC-A) na osnove normativnykh dannykh rossiiskoi populyatsii. Rossiiskii psikhiatricheskii zhurnal. 2015:2.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Янушко М.Г., Шаманина М.В., Аристова Т.А., Ричард К., Иванов М.В., Толмачева М. Стандартизация шкалы «Краткая оценка когнитивных функций у пациентов с аффективными расстройствами» (BAC-А) на основе нормативных данных российской популяции. Российский психиатрический журнал. 2015:2.</mixed-citation><mixed-citation xml:lang="en">Anderson R.J., Freedland K.E., Clouse R.E., Lustman, P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes care. 2001;24(6):1069-1078. Doi:10.2337/diacare.24.6.1069</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Anderson R.J., Freedland K.E., Clouse R.E., Lustman, P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes care. 2001;24(6):1069-1078. Doi:10.2337/diacare.24.6.1069</mixed-citation><mixed-citation xml:lang="en">Baptiste D.C., Hartwick A.T., Jollimore C.A., Baldridge W.H., Seigel G.M., Kelly M.E. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Molecular pharmacology. 2004;66(5):1113- 1122. Doi:10.1124/mol.104.001081</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Baptiste D.C., Hartwick A.T., Jollimore C.A., Baldridge W.H., Seigel G.M., Kelly M.E. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Molecular pharmacology. 2004;66(5):1113- 1122. Doi:10.1124/mol.104.001081</mixed-citation><mixed-citation xml:lang="en">Baune B.T., Brignone M., Larsen K.G. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. International Journal of Neuropsychopharmacology. 2018;21(2):97-107. doi:10.1093/ijnp/pyx070</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Baune B.T., Brignone M., Larsen K.G. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. International Journal of Neuropsychopharmacology. 2018;21(2):97-107. doi:10.1093/ijnp/pyx070</mixed-citation><mixed-citation xml:lang="en">Blier P., El Mansari M. Serotonin and beyond: therapeutics for major depression. Philosophical Transactions of the Royal Society B: Biological Sciences. 2013;368:1615, 20120536. doi:10.1098/rstb.2012.0536</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Blier P., El Mansari M. Serotonin and beyond: therapeutics for major depression. Philosophical Transactions of the Royal Society B: Biological Sciences. 2013;368:1615, 20120536. doi:10.1098/rstb.2012.0536</mixed-citation><mixed-citation xml:lang="en">Bortolato B., Miskowiak K.W., Köhler C.A., Maes M., Fernandes B.S., Berk M., Carvalho A.F. Cognitive remission: a novel objective for the treatment of major depression?. BMC medicine. 2016;14(1):9. Doi:10.1186/s12916-016-0560-3</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bortolato B., Miskowiak K.W., Köhler C.A., Maes M., Fernandes B.S., Berk M., Carvalho A.F. Cognitive remission: a novel objective for the treatment of major depression?. BMC medicine. 2016;14(1):9. Doi:10.1186/s12916-016-0560-3</mixed-citation><mixed-citation xml:lang="en">Braszko J.J., Karwowska-Polecka W., Halicka D., Gard P.R. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. Journal of basic and clinical physiology and pharmacology. 2003;14(4):323-344. Doi:10.1515/JBCPP.2003.14.4.323</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Braszko J.J., Karwowska-Polecka W., Halicka D., Gard P.R. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. Journal of basic and clinical physiology and pharmacology. 2003;14(4):323-344. Doi:10.1515/JBCPP.2003.14.4.323</mixed-citation><mixed-citation xml:lang="en">Cha D.S., Best M.W., Bowie C.R., Gallaugher L.A., Woldeyohannes H.O., Soczynska J.K., Lui J. P. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. Journal of Affective Disorders. 2017;210:57-65. doi:10.1016/j.jad.2016.12.006</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cha D.S., Best M.W., Bowie C.R., Gallaugher L.A., Woldeyohannes H.O., Soczynska J.K., Lui J. P. A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. Journal of Affective Disorders. 2017;210:57-65. doi:10.1016/j.jad.2016.12.006</mixed-citation><mixed-citation xml:lang="en">Crowe S.F., Stranks E.K. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Archives of Clinical Neuropsychology. 2018;33(7):901-911. doi:10.1093/arclin/acx120</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Crowe S.F., Stranks E.K. The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Archives of Clinical Neuropsychology. 2018;33(7):901-911. doi:10.1093/arclin/acx120</mixed-citation><mixed-citation xml:lang="en">Daskalakis Z.J., Dimitrova J., McClintock S.M., Sun Y., Voineskos D., Rajji T.K., Downar J. Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology. 2020;45(2):276- 282. doi:10.1038/s41386-019-0515-4</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Daskalakis Z.J., Dimitrova J., McClintock S.M., Sun Y., Voineskos D., Rajji T.K., Downar J. Magnetic seizure therapy (MST) for major depressive disorder. Neuropsychopharmacology. 2020;45(2):276- 282. doi:10.1038/s41386-019-0515-4</mixed-citation><mixed-citation xml:lang="en">Dean O.M., Kanchanatawan B., Ashton M., Mohebbi M., Ng C.H., Maes M., McKenzie H. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. Australian &amp; New Zealand Journal of Psychiatry. 2017;51(8):829-840. doi:10.1177/0004867417709357</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dean O.M., Kanchanatawan B., Ashton M., Mohebbi M., Ng C.H., Maes M., McKenzie H. Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial. Australian &amp; New Zealand Journal of Psychiatry. 2017;51(8):829-840. doi:10.1177/0004867417709357</mixed-citation><mixed-citation xml:lang="en">Dean O.M., Data-Franco J., Giorlando F., Berk M. (2012). Minocycline. CNS drugs, 26(5), 391-401. doi:10.2165/11632000-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dean O.M., Data-Franco J., Giorlando F., Berk M. (2012). Minocycline. CNS drugs, 26(5), 391-401. doi:10.2165/11632000-000000000-00000</mixed-citation><mixed-citation xml:lang="en">Dias V.V., Balanzá‐Martinez V., Soeiro‐de‐Souza M.G., Moreno R.A., Figueira M.L., Machado‐Vieira R., Vieta E. (2012). Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica, 126(5), 315-331. doi:10.1111/j.1600-0447.2012.01910.x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dias V.V., Balanzá‐Martinez V., Soeiro‐de‐Souza M.G., Moreno R.A., Figueira M.L., Machado‐Vieira R., Vieta E. (2012). Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatrica Scandinavica, 126(5), 315-331. doi:10.1111/j.1600-0447.2012.01910.x</mixed-citation><mixed-citation xml:lang="en">Elgamal S., MacQueen G. (2008). Galantamine as an adjunctive treatment in major depression. Journal of clinical psychopharmacology, 28(3), 357-359. doi:10.1097/JCP.0b013e318172756c</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Elgamal S., MacQueen G. (2008). Galantamine as an adjunctive treatment in major depression. Journal of clinical psychopharmacology, 28(3), 357-359. doi:10.1097/JCP.0b013e318172756c</mixed-citation><mixed-citation xml:lang="en">Fourrier C., Sampson E., Mills N.T., Baune B.T. (2018). Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials, 19(1), 447. doi:10.1186/s13063-018-2829-7</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fourrier C., Sampson E., Mills N.T., Baune B.T. (2018). Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials, 19(1), 447. doi:10.1186/s13063-018-2829-7</mixed-citation><mixed-citation xml:lang="en">Fregni F., Boggio P.S., Nitsche M.A., Rigonatti S.P., Pascual‐Leone A. (2006). Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depression and anxiety, 23(8), 482-484. doi:10.1002/da.20201</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fregni F., Boggio P.S., Nitsche M.A., Rigonatti S.P., Pascual‐Leone A. (2006). Cognitive effects of repeated sessions of transcranial direct current stimulation in patients with depression. Depression and anxiety, 23(8), 482-484. doi:10.1002/da.20201</mixed-citation><mixed-citation xml:lang="en">Furey M.L., Drevets W.C. (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Archives of general psychiatry, 63(10), 1121-1129. doi:10.1001/archpsyc.63.10.1121</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Furey M.L., Drevets W.C. (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Archives of general psychiatry, 63(10), 1121-1129. doi:10.1001/archpsyc.63.10.1121</mixed-citation><mixed-citation xml:lang="en">Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Guzmán D., Guàrdia-Olmos J., Hinojosa-Calvo, E. Herrera-Abarca J. E. (2009). Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of psychiatric research, 43(9), 855-863. doi:10.1016/j.jpsychires.2008.10.015</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Herrera-Guzmán I., Gudayol-Ferré E., Herrera-Guzmán D., Guàrdia-Olmos J., Hinojosa-Calvo, E. Herrera-Abarca J. E. (2009). Effects of selective serotonin reuptake and dual serotonergic–noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. Journal of psychiatric research, 43(9), 855-863. doi:10.1016/j.jpsychires.2008.10.015</mixed-citation><mixed-citation xml:lang="en">Husain M.I., Chaudhry I.B., Husain N., Khoso A.B., Rahman R.R., Hamirani M.M., Young A.H. (2017). Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. Journal of Psychopharmacology, 31(9), 1166-1175. doi:10.1177/0269881117724352</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Husain M.I., Chaudhry I.B., Husain N., Khoso A.B., Rahman R.R., Hamirani M.M., Young A.H. (2017). Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. Journal of Psychopharmacology, 31(9), 1166-1175. doi:10.1177/0269881117724352</mixed-citation><mixed-citation xml:lang="en">Kampf-Sherf O., Zlotogorski Z., Gilboa A., Speedie L., Lereya J., Rosca P., Shavit Y. (2004). Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. Journal of affective disorders, 82(3), 453-459. doi:10.1016/j.jad.2004.02.006</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kampf-Sherf O., Zlotogorski Z., Gilboa A., Speedie L., Lereya J., Rosca P., Shavit Y. (2004). Neuropsychological functioning in major depression and responsiveness to selective serotonin reuptake inhibitors antidepressants. Journal of affective disorders, 82(3), 453-459. doi:10.1016/j.jad.2004.02.006</mixed-citation><mixed-citation xml:lang="en">Kaser M., Deakin J.B., Michael A., Zapata C., Bansal R., Ryan D., Sahakian B.J. (2017). Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2(2), 115-122. doi:10.1016/j.bpsc.2016.11.009</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kaser M., Deakin J.B., Michael A., Zapata C., Bansal R., Ryan D., Sahakian B.J. (2017). Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2(2), 115-122. doi:10.1016/j.bpsc.2016.11.009</mixed-citation><mixed-citation xml:lang="en">Katona C.L., Katona C.P. (2014). New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatric disease and treatment, 10, 349. doi:10.2147/NDT.S39544</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Katona C.L., Katona C.P. (2014). New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatric disease and treatment, 10, 349. doi:10.2147/NDT.S39544</mixed-citation><mixed-citation xml:lang="en">Keefe R.S., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. The Journal of clinical psychiatry, 75(8), 864-876. doi:10.4088/JCP.13r08609</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Keefe R.S., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. (2014). Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. The Journal of clinical psychiatry, 75(8), 864-876. doi:10.4088/JCP.13r08609</mixed-citation><mixed-citation xml:lang="en">Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry, 164(7), 1061-1071. doi:10.1176/ajp.2007.164.7.1061</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Keefe R.S., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. (2007). Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry, 164(7), 1061-1071. doi:10.1176/ajp.2007.164.7.1061</mixed-citation><mixed-citation xml:lang="en">Khan A., Ginsberg L.D., Asnis G.M., Goodwin F.K., Davis K.H., Krishnan A.A., Adams B.E. (2004). Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. The Journal of clinical psychiatry, 65(11), 1483-1490. doi:10.4088/JCP.v65n1107</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Khan A., Ginsberg L.D., Asnis G.M., Goodwin F.K., Davis K.H., Krishnan A.A., Adams B.E. (2004). Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. The Journal of clinical psychiatry, 65(11), 1483-1490. doi:10.4088/JCP.v65n1107</mixed-citation><mixed-citation xml:lang="en">Kishi T., Matsunaga S., Iwata N. (2017). A meta-analysis of memantine for depression. Journal of Alzheimer’s Disease, 57(1), 113-121. doi:10.3233/JAD-161251</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Kishi T., Matsunaga S., Iwata N. (2017). A meta-analysis of memantine for depression. Journal of Alzheimer’s Disease, 57(1), 113-121. doi:10.3233/JAD-161251</mixed-citation><mixed-citation xml:lang="en">Knight M.J., Mills N.T., Baune B.T. (2019). Contemporary methods of improving cognitive dysfunction in clinical depression. Expert review of neurotherapeutics, 19(5), 431-443. doi:10.1080/14737175.2019.1610395</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Knight M.J., Mills N.T., Baune B.T. (2019). Contemporary methods of improving cognitive dysfunction in clinical depression. Expert review of neurotherapeutics, 19(5), 431-443. doi:10.1080/14737175.2019.1610395</mixed-citation><mixed-citation xml:lang="en">Listunova L., Roth C., Bartolovic M., Kienzle J., Bach C., Weisbrod M., Roesch-Ely D. (2018). Cognitive impairment along the course of depression: Non-pharmacological treatment options. Psychopathology, 51(5), 295-305. doi:10.1159/000492620</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Listunova L., Roth C., Bartolovic M., Kienzle J., Bach C., Weisbrod M., Roesch-Ely D. (2018). Cognitive impairment along the course of depression: Non-pharmacological treatment options. Psychopathology, 51(5), 295-305. doi:10.1159/000492620</mixed-citation><mixed-citation xml:lang="en">Lundbeck. FDA Updates TrintellixR (vortioxetine) Label to Include Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in acute Major Depressive Disorder (MDD). (2018). Дата обновления 02.05.2018, дата обращения 30.07.2020 Доступно на: https://globenewswire.com/newsre-lease/2018/05/02/1495434/0/en/FDA-updates-Trin-tellix-vortioxetine-label-to-include-data-showing-improvement-in-processing-speed-an-importantaspect-of-cognitivefunction-in-acute-Major-Depres-sive-Disorder-MDD.html</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Lundbeck. FDA Updates TrintellixR (vortioxetine) Label to Include Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in acute Major Depressive Disorder (MDD). (2018). Дата обновления 02.05.2018, дата обращения 30.07.2020 Доступно на: https://globenewswire.com/newsre-lease/2018/05/02/1495434/0/en/FDA-updates-Trin-tellix-vortioxetine-label-to-include-data-showing-improvement-in-processing-speed-an-importantaspect-of-cognitivefunction-in-acute-Major-Depres-sive-Disorder-MDD.html</mixed-citation><mixed-citation xml:lang="en">Madhoo M., Keefe R.S., Roth R.M., Sambunaris A., Wu J., Trivedi M.H., Lasser R. (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology, 39(6), 1388-1398. doi:10.1038/npp.2013.334</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Madhoo M., Keefe R.S., Roth R.M., Sambunaris A., Wu J., Trivedi M.H., Lasser R. (2014). Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology, 39(6), 1388-1398. doi:10.1038/npp.2013.334</mixed-citation><mixed-citation xml:lang="en">Mahableshwarkar A.R., Zajecka J., Jacobson W., Chen Y., Keefe R.S. (2015). A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology, 40(8), 2025-2037. doi:10.1038/npp.2015.52</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Mahableshwarkar A.R., Zajecka J., Jacobson W., Chen Y., Keefe R.S. (2015). A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology, 40(8), 2025-2037. doi:10.1038/npp.2015.52</mixed-citation><mixed-citation xml:lang="en">Masand P.S. (2003). Tolerability and adherence issues in antidepressant therapy. Clinical therapeutics, 25(8), 2289-2304.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Masand P.S. (2003). Tolerability and adherence issues in antidepressant therapy. Clinical therapeutics, 25(8), 2289-2304.</mixed-citation><mixed-citation xml:lang="en">McFarland A.J., Anoopkumar-Dukie S., Arora D.S., Grant G.D., McDermott C.M., Perkins A.V., Davey A.K. (2014). Molecular mechanisms underlying the effects of statins in the central nervous system. International journal of molecular sciences, 15(11), 20607-20637. doi:10.3390/ijms151120607</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">McFarland A.J., Anoopkumar-Dukie S., Arora D.S., Grant G.D., McDermott C.M., Perkins A.V., Davey A.K. (2014). Molecular mechanisms underlying the effects of statins in the central nervous system. International journal of molecular sciences, 15(11), 20607-20637. doi:10.3390/ijms151120607</mixed-citation><mixed-citation xml:lang="en">McIntyre R.S., Cha D.S., Soczynska J.K., Woldeyohannes H.O., Gallaugher L.A., Kudlow P., Baskaran A. (2013). Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression and anxiety, 30(6), 515-527. doi:10.1002/da.22063</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">McIntyre R.S., Cha D.S., Soczynska J.K., Woldeyohannes H.O., Gallaugher L.A., Kudlow P., Baskaran A. (2013). Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depression and anxiety, 30(6), 515-527. doi:10.1002/da.22063</mixed-citation><mixed-citation xml:lang="en">Millan M.J., Agid Y., Brüne M., Bullmore E.T., Carter C.S., Clayton N.S., Dubois B. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews Drug discovery, 11(2), 141-168. doi:10.1038/nrd3628</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Millan M.J., Agid Y., Brüne M., Bullmore E.T., Carter C.S., Clayton N.S., Dubois B. (2012). Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews Drug discovery, 11(2), 141-168. doi:10.1038/nrd3628</mixed-citation><mixed-citation xml:lang="en">Misiak B., Beszłej J.A., Kotowicz K., Szewczuk-Bogusławska M., Samochowiec J., Kucharska-Mazur J., Frydecka D. (2018). Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 80, 177-188. doi:10.1016/j.pnpbp.2017.04.021</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Misiak B., Beszłej J.A., Kotowicz K., Szewczuk-Bogusławska M., Samochowiec J., Kucharska-Mazur J., Frydecka D. (2018). Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 80, 177-188. doi:10.1016/j.pnpbp.2017.04.021</mixed-citation><mixed-citation xml:lang="en">Miskowiak K., Inkster B., O’Sullivan U., Selvaraj S., Goodwin G.M., Harmer C.J. (2008). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Experimental brain research, 184(3), 313-321.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Miskowiak K., Inkster B., O’Sullivan U., Selvaraj S., Goodwin G.M., Harmer C.J. (2008). Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Experimental brain research, 184(3), 313-321.</mixed-citation><mixed-citation xml:lang="en">Miskowiak K.W., Vinberg M., Christensen E.M., Bukh J.D., Harmer C.J., Ehrenreich H., Kessing L.V. (2014). Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology, 39(6), 1399-1408. doi:10.1038/npp.2013.335</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Miskowiak K.W., Vinberg M., Christensen E.M., Bukh J.D., Harmer C.J., Ehrenreich H., Kessing L.V. (2014). Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology, 39(6), 1399-1408. doi:10.1038/npp.2013.335</mixed-citation><mixed-citation xml:lang="en">Miskowiak K.W., Ott C.V., Petersen J.Z., Kessing L.V. (2016). Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European Neuropsychopharmacology, 26(12), 1845-1867. doi:10.1016/j.euroneuro.2016.09.641</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Miskowiak K.W., Ott C.V., Petersen J.Z., Kessing L.V. (2016). Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field. European Neuropsychopharmacology, 26(12), 1845-1867. doi:10.1016/j.euroneuro.2016.09.641</mixed-citation><mixed-citation xml:lang="en">Mohn C., Rund B.R. (2019). Neurognitive function and symptom remission 2 years after ECT in major depressive disorders. Journal of Affective Disorders, 246, 368-375. doi:10.1016/j.jad.2018.12.083</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mohn C., Rund B.R. (2019). Neurognitive function and symptom remission 2 years after ECT in major depressive disorders. Journal of Affective Disorders, 246, 368-375. doi:10.1016/j.jad.2018.12.083</mixed-citation><mixed-citation xml:lang="en">Mospan C.M. Are statins protective or harmful to cognitive function? Journal of the American Academy of Pas. 2016;29(1):11-12.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Mospan C.M. Are statins protective or harmful to cognitive function? Journal of the American Academy of Pas. 2016;29(1):11-12.</mixed-citation><mixed-citation xml:lang="en">Nierenberg A.A., Loft H., Olsen C.K. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders. 2019;250:35-42.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Nierenberg A.A., Loft H., Olsen C.K. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders. 2019;250:35-42.</mixed-citation><mixed-citation xml:lang="en">Ortinski P., Meador K.J. Cognitive side effects of antiepileptic drugs. Epilepsy &amp; Behavior. 2004;5:60-65. doi:10.1016/j.yebeh.2003.11.008</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Ortinski P., Meador K.J. Cognitive side effects of antiepileptic drugs. Epilepsy &amp; Behavior. 2004;5:60-65. doi:10.1016/j.yebeh.2003.11.008</mixed-citation><mixed-citation xml:lang="en">Ott C.V., Vinberg M., Kessing L.V., Miskowiak K.W. The effect of erythropoietin on cognition in affective disorders–Associations with baseline deficits and change in subjective cognitive complaints. European Neuropsychopharmacology. 2016;26(8):1264-1273. doi:10.1016/j.euroneuro.2016.05.009</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Ott C.V., Vinberg M., Kessing L.V., Miskowiak K.W. The effect of erythropoietin on cognition in affective disorders–Associations with baseline deficits and change in subjective cognitive complaints. European Neuropsychopharmacology. 2016;26(8):1264-1273. doi:10.1016/j.euroneuro.2016.05.009</mixed-citation><mixed-citation xml:lang="en">Pehrson A.L., Hillhouse T.M., Haddjeri N., Rovera R., Porter J.H., Mørk A., Sanchez C. Task- and Treatment Length–Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. Journal of Pharmacology and Experimental Therapeutics. 2016;358(3):472-482. doi:10.1124/jpet.116.233924</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Pehrson A.L., Hillhouse T.M., Haddjeri N., Rovera R., Porter J.H., Mørk A., Sanchez C. Task- and Treatment Length–Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. Journal of Pharmacology and Experimental Therapeutics. 2016;358(3):472-482. doi:10.1124/jpet.116.233924</mixed-citation><mixed-citation xml:lang="en">Pelton G.H., Harper O.L., Roose S.P., Marder K., D’Antonio K., Devanand D.P. Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry. 2016;31(6):648-655. doi:10.1002/gps.4375</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Pelton G.H., Harper O.L., Roose S.P., Marder K., D’Antonio K., Devanand D.P. Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study. International Journal of Geriatric Psychiatry. 2016;31(6):648-655. doi:10.1002/gps.4375</mixed-citation><mixed-citation xml:lang="en">Prado C.E., Watt S., Crowe S.F. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychology review. 2018;28(1):32-72. doi:10.1007/s11065-018-9369-5</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Prado C.E., Watt S., Crowe S.F. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples. Neuropsychology review. 2018;28(1):32-72. doi:10.1007/s11065-018-9369-5</mixed-citation><mixed-citation xml:lang="en">Pu S., Setoyama S., Noda T. Association between cognitive deficits and suicidal ideation in patients with major depressive disorder. Scientific reports. 2017;7(1):1-6. doi:10.1038/s41598-017-12142-8</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Pu S., Setoyama S., Noda T. Association between cognitive deficits and suicidal ideation in patients with major depressive disorder. Scientific reports. 2017;7(1):1-6. doi:10.1038/s41598-017-12142-8</mixed-citation><mixed-citation xml:lang="en">Rigal A., Mouchabac S., Peretti C.S. Interest of scopolamine as a treatment of major depressive disorder. L’Encephale. 2016;42(6):568.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Rigal A., Mouchabac S., Peretti C.S. Interest of scopolamine as a treatment of major depressive disorder. L’Encephale. 2016;42(6):568.</mixed-citation><mixed-citation xml:lang="en">Roca M., López-Navarro E., Monzón S., Vives M., García-Toro M., García-Campayo J., Gili M. Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. European Neuropsychopharmacology. 2015;25(11):1991-1998. doi:10.1016/j.euroneuro.2015.07.020</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Roca M., López-Navarro E., Monzón S., Vives M., García-Toro M., García-Campayo J., Gili M. Cognitive impairment in remitted and non-remitted depressive patients: A follow-up comparison between first and recurrent episodes. European Neuropsychopharmacology. 2015;25(11):1991-1998. doi:10.1016/j.euroneuro.2015.07.020</mixed-citation><mixed-citation xml:lang="en">Roiser J.P., Sahakian B.J. Hot and cold cognition in depression. CNS spectrums. 2013;18(3):139-149. doi:10.1017/S1092852913000072</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Roiser J.P., Sahakian B.J. Hot and cold cognition in depression. CNS spectrums. 2013;18(3):139-149. doi:10.1017/S1092852913000072</mixed-citation><mixed-citation xml:lang="en">Rosenblat J.D., Kakar R., McIntyre R.S. (2016). The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. International Journal of Neuropsychopharmacology, 19(2). doi:10.1093/ijnp/pyv082</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenblat J.D., Kakar R., McIntyre R.S. (2016). The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. International Journal of Neuropsychopharmacology, 19(2). doi:10.1093/ijnp/pyv082</mixed-citation><mixed-citation xml:lang="en">Russo M., Mahon K., Burdick K.E. (2015). Measuring cognitive function in MDD: emerging assessment tools. Depression and anxiety, 32(4), 262-269.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Russo M., Mahon K., Burdick K.E. (2015). Measuring cognitive function in MDD: emerging assessment tools. Depression and anxiety, 32(4), 262-269.</mixed-citation><mixed-citation xml:lang="en">Sanchez C., Asin K.E., Artigas F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology &amp; therapeutics, 145, 43-57. doi:10.1016/j.pharmthera.2014.07.001</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez C., Asin K.E., Artigas F. (2015). Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacology &amp; therapeutics, 145, 43-57. doi:10.1016/j.pharmthera.2014.07.001</mixed-citation><mixed-citation xml:lang="en">Sarter M., Lustig C., Taylor S.F. (2012). Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology, 62(3), 1544-1553. doi:10.1016/j.neuropharm.2010.12.001</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Sarter M., Lustig C., Taylor S.F. (2012). Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology, 62(3), 1544-1553. doi:10.1016/j.neuropharm.2010.12.001</mixed-citation><mixed-citation xml:lang="en">Scuteri A., Spazzafumo L., Cipriani L., Gianni W., Corsonello A., Cravello L., Sebastiani M. (2011). Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Archives of gerontology and geriatrics, 52(3), 253-257. doi:10.1016/j.archger.2010.04.002</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Scuteri A., Spazzafumo L., Cipriani L., Gianni W., Corsonello A., Cravello L., Sebastiani M. (2011). Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Archives of gerontology and geriatrics, 52(3), 253-257. doi:10.1016/j.archger.2010.04.002</mixed-citation><mixed-citation xml:lang="en">Semkovska M., Quinlivan L., O’Grady T., Johnson R., Collins A., O’Connor J., Gload T. (2019). Cognitive function following a major depressive episode: a systematic review and meta-analysis. The Lancet Psychiatry, 6(10), 851-861. doi:10.1016/S2215-0366(19)30291-3</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Semkovska M., Quinlivan L., O’Grady T., Johnson R., Collins A., O’Connor J., Gload T. (2019). Cognitive function following a major depressive episode: a systematic review and meta-analysis. The Lancet Psychiatry, 6(10), 851-861. doi:10.1016/S2215-0366(19)30291-3</mixed-citation><mixed-citation xml:lang="en">Semkovska M., Ahern E. (2017). Online neurocognitive remediation therapy to improve cognition in community-living individuals with a history of depression: A pilot study. Internet Interventions, 9, 7-14. doi:10.1016/j.invent.2017.04.003</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Semkovska M., Ahern E. (2017). Online neurocognitive remediation therapy to improve cognition in community-living individuals with a history of depression: A pilot study. Internet Interventions, 9, 7-14. doi:10.1016/j.invent.2017.04.003</mixed-citation><mixed-citation xml:lang="en">Shemesh E., Rudich A., Harman-Boehm I., Cuk- ierman-Yaffe T. (2012). Effect of intranasal insulin on cognitive function: a systematic review. The Journal of Clinical Endocrinology &amp; Metabolism, 97(2), 366-376. doi:10.1210/jc.2011-1802</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Shemesh E., Rudich A., Harman-Boehm I., Cuk- ierman-Yaffe T. (2012). Effect of intranasal insulin on cognitive function: a systematic review. The Journal of Clinical Endocrinology &amp; Metabolism, 97(2), 366-376. doi:10.1210/jc.2011-1802</mixed-citation><mixed-citation xml:lang="en">Silberner J. (2019). Ketamine based drug should be available for treatment resistant depression, says FDA panel.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Silberner J. (2019). Ketamine based drug should be available for treatment resistant depression, says FDA panel.</mixed-citation><mixed-citation xml:lang="en">Soh J.F., Almadani A., Beaulieu S., Rajji T., Mulsant B. H., Su C.L., Schaffer A. (2020). The effect of atorvastatin on cognition and mood in bipola disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of affective disorders, 262, 149-154.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Soh J.F., Almadani A., Beaulieu S., Rajji T., Mulsant B. H., Su C.L., Schaffer A. (2020). The effect of atorvastatin on cognition and mood in bipola disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. Journal of affective disorders, 262, 149-154.</mixed-citation><mixed-citation xml:lang="en">Spielman L.J., Little J.P., Klegeris A. (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of neuroimmunology, 273(1-2), 8-21. doi:10.1016/j.jneuroim.2014.06.004</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Spielman L.J., Little J.P., Klegeris A. (2014). Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. Journal of neuroimmunology, 273(1-2), 8-21. doi:10.1016/j.jneuroim.2014.06.004</mixed-citation><mixed-citation xml:lang="en">Stranks E.K., Crowe S.F. (2014). The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. Journal of clinical and experimental neuropsychology, 36(7), 691-700. doi:10.1080/13803395.2014.928268</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Stranks E.K., Crowe S.F. (2014). The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. Journal of clinical and experimental neuropsychology, 36(7), 691-700. doi:10.1080/13803395.2014.928268</mixed-citation><mixed-citation xml:lang="en">Strzelecki D., Tabaszewska A., Barszcz Z., Józefowicz O., Kropiwnicki P., Rabe-Jabłońska J. (2013). A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry Investigation, 10(4), 421. doi:10.4306/pi.2013.10.4.421</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Strzelecki D., Tabaszewska A., Barszcz Z., Józefowicz O., Kropiwnicki P., Rabe-Jabłońska J. (2013). A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry Investigation, 10(4), 421. doi:10.4306/pi.2013.10.4.421</mixed-citation><mixed-citation xml:lang="en">Timm C., Rachota-Ubl B., Beddig T., Zamoscik V.E., Ebner-Priemer U., Reinhard I., Kuehner C. (2018). Mindfulness-based attention training improves cognitive and affective processes in daily life in remitted patients with recurrent depression: a randomized controlled trial. Psychotherapy and psychosomatics, 87(3). doi:10.1159/000488862</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Timm C., Rachota-Ubl B., Beddig T., Zamoscik V.E., Ebner-Priemer U., Reinhard I., Kuehner C. (2018). Mindfulness-based attention training improves cognitive and affective processes in daily life in remitted patients with recurrent depression: a randomized controlled trial. Psychotherapy and psychosomatics, 87(3). doi:10.1159/000488862</mixed-citation><mixed-citation xml:lang="en">Veselinović T., Scharpenberg M., Heinze M., Cordes J., Mühlbauer B., Juckel G., Bleich S. (2019). Disparate effects of first and second generation anti-psychotics on cognition in schizophrenia–Findings from the randomized NeSSy trial. European Neuropsychopharmacology, 29(6), 720-739. doi:10.1016/j.euroneuro.2019.03.014</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Veselinović T., Scharpenberg M., Heinze M., Cordes J., Mühlbauer B., Juckel G., Bleich S. (2019). Disparate effects of first and second generation anti-psychotics on cognition in schizophrenia–Findings from the randomized NeSSy trial. European Neuropsychopharmacology, 29(6), 720-739. doi:10.1016/j.euroneuro.2019.03.014</mixed-citation><mixed-citation xml:lang="en">Wang J., Vila-Rodriguez F., Ge R., Gao S., Gregory E., Jiang W., Wang G. (2020). Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: A pilot study. Journal of Affective Disorders, 264, 215-220. doi:10.1016/j.jad.2019.12.022</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J., Vila-Rodriguez F., Ge R., Gao S., Gregory E., Jiang W., Wang G. (2020). Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: A pilot study. Journal of Affective Disorders, 264, 215-220. doi:10.1016/j.jad.2019.12.022</mixed-citation><mixed-citation xml:lang="en">Wingo A.P., Wingo T.S., Harvey P.D., Baldessarini R.J. (2009). Effects of lithium on cognitive performance: a meta-analysis. In Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK). doi:10.4088/JCP.08r04972</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Wingo A.P., Wingo T.S., Harvey P.D., Baldessarini R.J. (2009). Effects of lithium on cognitive performance: a meta-analysis. In Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK). doi:10.4088/JCP.08r04972</mixed-citation><mixed-citation xml:lang="en">Wolkenstein L., Plewnia C. (2013). Amelioration of cognitive control in depression by transcranial direct current stimulation. Biological psychiatry, 73(7), 646-651. doi:10.1016/j.biopsych.2012.10.010</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Wolkenstein L., Plewnia C. (2013). Amelioration of cognitive control in depression by transcranial direct current stimulation. Biological psychiatry, 73(7), 646-651. doi:10.1016/j.biopsych.2012.10.010</mixed-citation><mixed-citation xml:lang="en">Xiao L., Feng L., Zhu X.Q., Feng Y., Wu W.Y., Ungvari G.S., Wang G. (2018). Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study. Psychiatry research, 261, 547-553. doi:10.1016/j.psychres.2018.01.020</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao L., Feng L., Zhu X.Q., Feng Y., Wu W.Y., Ungvari G.S., Wang G. (2018). Comparison of residual depressive symptoms and functional impairment between fully and partially remitted patients with major depressive disorder: a multicenter study. Psychiatry research, 261, 547-553. doi:10.1016/j.psychres.2018.01.020</mixed-citation><mixed-citation xml:lang="en">Yatham M.S., Yatham K.S., Ravindran A.V., Sullivan F. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. Journal of affective disorders. 2018;257:55-63. doi:10.1016/j.jad.2019.07.002</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Yatham M.S., Yatham K.S., Ravindran A.V., Sullivan F. Do statins have an effect on depressive symptoms? A systematic review and meta-analysis. Journal of affective disorders. 2018;257:55-63. doi:10.1016/j.jad.2019.07.002</mixed-citation><mixed-citation xml:lang="en">Zavodnick A.D., Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly. 2012;83(3):371-383. doi:10.1007/s11126-012-9208-4</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Zavodnick A.D., Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly. 2012;83(3):371-383. doi:10.1007/s11126-012-9208-4</mixed-citation><mixed-citation xml:lang="en">Zheng W., Zhu X.M., Zhang Q.E., Cheng G., Cai D.B., He J., Xiang Y.T. Adjunctive minocycline for major mental disorders: a systematic review. Journal of Psychopharmacology. 2019;33(10):1215-1226. doi:10.1177/0269881119858286</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng W., Zhu X.M., Zhang Q.E., Cheng G., Cai D.B., He J., Xiang Y.T. Adjunctive minocycline for major mental disorders: a systematic review. Journal of Psychopharmacology. 2019;33(10):1215-1226. doi:10.1177/0269881119858286</mixed-citation><mixed-citation xml:lang="en">Zuckerman H., Pan Z., Park C., Brietzke E., Musial N., Shariq A.S., McIntyre R.S. Recognition and treatment of cognitive dysfunction in major depressive disorder. Frontiers in Psychiatry. 2018;9:655. doi:10.3389/fpsyt.2018.00655</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Zuckerman H., Pan Z., Park C., Brietzke E., Musial N., Shariq A.S., McIntyre R.S. Recognition and treatment of cognitive dysfunction in major depressive disorder. Frontiers in Psychiatry. 2018;9:655. doi:10.3389/fpsyt.2018.00655</mixed-citation><mixed-citation xml:lang="en">Zuckerman H., Pan Z., Park C., Brietzke E., Musial N., Shariq A.S., McIntyre R.S. Recognition and treatment of cognitive dysfunction in major depressive disorder. Frontiers in Psychiatry. 2018;9:655. doi:10.3389/fpsyt.2018.00655</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
